Clinical Trial

Phase 2 Clinical Trial of KH617

Name: Phase 2 Clinical Trial of KH617 — clinical trial record (NCT07138001)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma

Trial Details

NCT Number	NCT07138001
Lead Sponsor	Sichuan Honghe Biotechnology Co., Ltd.
Conditions	Recurrent Glioblastoma
Enrollment	60 participants
Start Date	2025-08
Primary Completion	2027-09 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-22